Market Access Impact (US) [Growth Hormone Deficiency]
What stops doctors from prescribing your brand? It may be more than one thing
Market barriers affect over 20% of growth hormone prescriptions in the US, and most brands lose market share because of them. According to the endocrinologists we surveyed, that’s a problem with no single solution; many of them experience as many as 3 different barriers with any given brand.
Find out which barriers cost your brand the most market share, which competitors are taking it from you, and what you can do to win it back, in Market Access Impact: GHD (US).
Based on a survey of 100 adult- and paediatric endocrinologists, the report covers 7 major therapies from Aeterna Zentaris, Eli Lilly, EMD Serono, Ferring, Novo Nordisk, Pfizer, Roche, and Sandoz. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.
Top Takeaways
Market Access Impact: GHD (US) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access
We surveyed 100 US-based adult and paediatric endocrinologists, chosen from the largest community of validated physicians in the world
All respondents have
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Market barriers affect over 20% of growth hormone prescriptions in the US, and most brands lose market share because of them. According to the endocrinologists we surveyed, that’s a problem with no single solution; many of them experience as many as 3 different barriers with any given brand.
Find out which barriers cost your brand the most market share, which competitors are taking it from you, and what you can do to win it back, in Market Access Impact: GHD (US).
Based on a survey of 100 adult- and paediatric endocrinologists, the report covers 7 major therapies from Aeterna Zentaris, Eli Lilly, EMD Serono, Ferring, Novo Nordisk, Pfizer, Roche, and Sandoz. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.
Top Takeaways
- Most brands lose out: While every brand wins and loses share because of barriers, 4 of the 7 surveyed brands see a net loss.
- Barriers skew the top of the market: The 3rd-place brand takes a 6% market share hit. Without barriers, it would rocket up to 1st-place.
- One brand leads the table. Another can’t catch a break: Find out which brand sees a net share gain from every other surveyed brand, and which one sees a net loss to every other brand.
- No single barrier is to blame: 25% to nearly 40% of surveyed doctors experience 3 or more barriers with the surveyed brands.
- Some brands have a perception problem: Up to 20% of doctors either wouldn’t consider prescribing three of the surveyed brands, or haven’t heard of them at all.
- Cost is a huge problem for one brand: Over 40% of doctors experience cost barriers with this brand. That’s at least 10% more than any competitor.
- Genotropin (somatropin; Pfizer)
- Humatrope (somatropin; Eli Lilly)
- Norditropin (somatropin; Novo Nordisk)
- NutropinAq (somatropin; Roche)
- Omnitrope (somatropin; Sandoz)
- Saizen (somatropin; EMD Serono/Aeterna Zentaris)
- Zomacton (somatropin; Ferring)
Market Access Impact: GHD (US) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest impact?
- How many doctors prescribe your brand? How many don’t, but would consider it?
- Why don’t doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
We surveyed 100 US-based adult and paediatric endocrinologists, chosen from the largest community of validated physicians in the world
All respondents have
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with GHD in total in the last month
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. WHAT ARE MARKET BARRIERS?
2. ABOUT THIS REPORT
3. ABOUT THE SURVEY
4. BRANDS INCLUDED IN THE SURVEY
5. EXECUTIVE SUMMARY
2. ABOUT THIS REPORT
3. ABOUT THE SURVEY
4. BRANDS INCLUDED IN THE SURVEY
5. EXECUTIVE SUMMARY
